Ibrutinib
- PDF / 169,900 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 46 Downloads / 153 Views
1
S
Chronic hepatitis E virus infection, bacterial infection and septicaemia: 4 case reports In a study of 150 patients conducted from 2014 to 2019, 4 patients (2 men and 2 women) aged 59–76 years were described, who developed chronic hepatitis E virus (HEV) infection during treatment with ibrutinib for chronic lymphocytic leukaemia. Out of these 4 patients, one patient died due to bacterial infection and septicaemia following treatment with ibrutinib [not all durations of treatments to reactions onset stated]. The patients, who had chronic lymphocytic leukaemia, started receiving ibrutinib [dosages and routes not stated]. The patients were diagnosed with HEV infection 2–6 months after the initiation of ibrutinib. Consequently, the patients started receiving treatment with ribavirin and ibrutinib was not discontinued. At last follow-up, the HEV viral load was undetectable in 3/4 patients and the HEV viral load had decreased in 1/4 patients. Of these 4 patients, one patient died due to secondary cancer (aggressive cutaneous T-cell lymphoma) of an unknown aetiology, one patient died due to pulmonary embolism of an unknown aetiology, one patient died due to bacterial infection and septicaemia secondary to ibrutinib. The remaining one patient was alive and continued to take ibrutinib. Author comment: "Among ibrutinib-related infections, viral hepatitis are poorly described." "We report our singlecenter experience with 4 cases of chronic hepatitis E virus infection and their management with ribavirin." Protin C, et al. Ribavirin for Chronic Hepatitis e Virus Infection in IbrutinibExposed Patients. Open Forum Infectious Diseases 6: No. 9, 28 Jul 2019. 803437309 Available from: URL: http://doi.org/10.1093/ofid/ofz345 - France
0114-9954/19/1781-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 30 Nov 2019 No. 1781
Data Loading...
